US 12,385,926 B2 · MMP-8 as a marker for identifying infectious disease

Abstract

The invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of an infectious disease in a subject, wherein said method comprises providing a sample of said subject; determining a level of matrix metalloprotease-8 (MMP-8) or fragment(s) thereof in a sample of said subject, wherein said level of MMP-8 or fragment(s) thereof distinguishes between the presence and absence of an infectious disease in a patient with symptoms of a systemic inflammatory condition. In a preferred embodiment the invention relates to the determination of procalcitonin (PCT) and MMP-8 and their combined use to distinguish between the presence and absence of infectious disease in patients with symptoms of systemic inflammatory condition. The invention also relates to a computer-implemented method and a kit for conducting the method of the invention.

Claims12

Dependent claims

A method for diagnosis and treatment of bacterial sepsis, severe sepsis and/or septic shock in a subject, wherein said method comprises:

providing a sample from said subject wherein the subject has symptoms of a systemic inflammatory response syndrome (SIRS) or dyspnea;
measuring the metalloprotease-8 (MMP-8) in the sample from said subject,
wherein when the level of MMP-8 in the sample of said subject is above a reference level, threshold value and/or a population average corresponding to MMP-8 level in subjects with a systemic inflammatory response syndrome (SIRS) or dyspnea without an infection, the said level of MMP-8 being indicative of the presence of a bacterial sepsis, severe sepsis, and/or septic shock in said subject, the method comprises administering to said subject an effective amount of an antibiotic.

Dependencies are inferred from the claim text.

Facts

Application

16/617,622Filed 31 May 2018

Priority

EP 1717372431 May 2017

Published

US 2020/0225248 A116 Jul 2020

Granted

12 Aug 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

G01N 33/6893
Involving proteins, peptides or amino acids: related to diseases not provided for elsewhere
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
G01N 2333/988
Enzymes; Proenzymes: lyases , e.g. aldolases, heparinase, enolases, fumarase
G01N 2800/102
Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis: arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

MMP-8 as a marker for identifying infectious disease

Life of this patent

MMP-8 as a marker for identifying infectious disease

Life of this patent

Abstract

Claims12